Shattuck Labs, Inc. (STTK)
| Market Cap | 489.86M +309.6% |
| Revenue (ttm) | n/a -82.5% |
| Net Income | -67.72M |
| EPS | -0.51 |
| Shares Out | 101.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,320,324 |
| Open | 4.990 |
| Previous Close | 5.050 |
| Day's Range | 4.695 - 5.030 |
| 52-Week Range | 1.720 - 8.330 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 15.40 (+220.17%) |
| Earnings Date | Nov 5, 2026 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical... [Read more]
Financial Performance
In 2025, Shattuck Labs's revenue was $1.00 million, a decrease of -82.52% compared to the previous year's $5.72 million. Losses were -$48.81 million, -35.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for STTK stock is "Strong Buy." The 12-month stock price target is $15.4, which is an increase of 220.17% from the latest price.
News
Shattuck Labs reports Q3 EPS (14c), consensus (11c)
“We are very excited to begin Phase 2 clinical development with SL-325 in both Crohn’s disease and hidradenitis suppurativa. We believe these two studies will allow direct comparisons with the…
Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn's disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-3...
Shattuck Labs Quarterly report: Q3 2026
Shattuck Labs has published its Q3 2026 quarterly earnings report on November 5, 2026.
Shattuck Labs Earnings release: Q3 2026
Shattuck Labs released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Shattuck Labs Slides: Corporate presentation
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of pot...
Shattuck Labs initiated with a Buy at UBS
UBS initiated coverage of Shattuck Labs (STTK) with a Buy rating and $17 price target The firm believes the company’s lead asset, SL-325, may offer a “meaningful advantage” over first-generation…
Shattuck Labs price target raised to $14 from $11 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Shattuck Labs (STTK) to $14 from $11 and keeps an Outperform rating on the shares. The firm notes the company…
Shattuck Labs price target raised to $19 from $17 at Needham
Needham analyst Joseph Stringer raised the firm’s price target on Shattuck Labs (STTK) to $19 from $17 and keeps a Buy rating on the shares after the company announced its…
Shattuck Labs Slides: Corporate presentation
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Shattuck Labs to evaluate SL-325 in Phase 2 trial, appoints Ravichandran as SVP
Shattuck Labs (STTK) announced its plans to evaluate SL-325 in a Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa. RECEPTIVE-HS1 Phase 2 clinical trial in patients…
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
– RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first ha...
Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright
After Merck (MRK) presented Phase 2b data for tulisokibart in moderate-to-severe hidradenitis suppurativa at the EADV Congress and reported that it met the primary endpoint and will be advancing into…
Shattuck Labs management to meet with Piper Sandler
Meeting to be held on October 1 hosted by Piper Sandler.
Shattuck Labs Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The session highlighted a differentiated approach to immune modulation by targeting DR3, with promising phase I data showing durable receptor occupancy and low immunogenicity. Clinical development is focused on Crohn's disease, with plans to expand into HS and psoriatic arthritis, and a bispecific pipeline in progress.
Shattuck Labs Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing DR3 blockade as a differentiated approach in IBD, aiming for superior maintenance efficacy and lower immunogenicity compared to TL1A and IL-23 therapies. Key trials are underway, with induction data expected in H1 2028, and a strong cash position supports ongoing and future programs.
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of po...
Shattuck Labs initiated with a Strong Buy at Raymond James
Raymond James analyst Martin Auster initiated coverage of Shattuck Labs (STTK) with a Strong Buy rating and $18 price target SL-325 could offer a differentiated approach to the more than…
Shattuck Labs price target lowered to $14 from $18 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Shattuck Labs (STTK) to $14 from $18 and keeps a Buy rating on the shares after the company announced…
Shattuck Labs Quarterly report: Q2 2026
Shattuck Labs has published its Q2 2026 quarterly earnings report on August 11, 2026.
Shattuck Labs Earnings release: Q2 2026
Shattuck Labs released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Shattuck Labs Slides: Corporate presentation
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Shattuck Labs reports Q2 EPS (12c), consensus (12c)
As of June 30, 2026, cash and cash equivalents and short-term investments were $208.3M, as compared to $50.5 million as of June 30, 2025, expected to fund operations into 2029.
Shattuck Labs initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of Shattuck Labs (STTK) with an Overweight rating and $10 price target Shattuck is a clinical-stage biotech developing an anti-DR3 antibody program with...
Shattuck Labs initiated with an Outperform at Leerink
Leerink initiated coverage of Shattuck Labs (STTK) with an Outperform rating and $16 price target The firm says the company has constructed a potentially differentiated pipeline centered around target...